TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05229861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
Study: NCT05062954

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins
Description: Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
Study: NCT05323422

Intervention type: PROCEDURE
Intervention: intravenous Ketamine induction
Description: preoperatively ketamine wll administer in group 1-3

Intervention type: PROCEDURE
Intervention: intravenous Ketamine induction
Description: preoperatively ketamine wll administer in group 1-3
Study: NCT05975853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural beat music group (BBM group)
Description: The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) with BBM embedded.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) without BBM embedded.
Study: NCT04903600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics fruit vegetable fiber powder product
Description: Eat 16 g for once, and twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eat 16 g for once, and twice a day
Study: NCT06091878

Intervention type: OTHER
Intervention: Observation
Description: Observational study, no intervention
Study: NCT06261411

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: Diagnostic ultrasound of pulmonary tissues such as pleura, plural spaces, and parenchyma.
Study: NCT05768373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Clinpro™ Fluoride Aqueous Solution
Description: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M™ Vanish™
Description: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
Study: NCT05959681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garment with Vari-pad microdots ink-printed on inside.
Description: Initially, participants wear a garment with Vari-pads on one side (left or right) only and swap to a garment with Vari-pads on both sides if / when the participants notice a difference between the sides. Wearing garment 8 hours per 24 hours.
Study: NCT05505292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: Dosed twice a day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lifitegrast Ophthalmic Solution Vehicle
Description: Dosed twice a day for 8 weeks
Study: NCT06070714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser with pulse modulation
Description: The holmium laser with pulse modulation emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium fiber laser
Description: The thulium fiber laser has a different wavelength then the holmium laser with pulse modulation and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns.
Study: NCT05406284

Intervention type: PROCEDURE
Intervention: double kissing nano culotte stenting
Description: patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique
Study: NCT06648811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain management after surgery
Description: Kinesio tapes will be applied to the patients in the study group after gynecological laparoscopic operations. The routine pain management will also be provided in these patients in addition to the kinesio tapes. Only postoperative pain management will be provided to the patients in the control group. The patients will be consisted of only the patients who will be operated laparoscopically for gynecological diseases.
Study: NCT06384976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: Anti-CD19 CAR-T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: CYC/FLU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD20 mAB
Description: Anti-CD20 mAB
Study: NCT06243562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined exercises and progressive muscle relaxation group
Description: Participants in the intervention group will receive a combined exercise program that will last 45-60 minutes, 3 days a week for 8 weeks, and progressive muscle relaxation training that will last 10-15 minutes, under the supervision of a therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined exercises group
Description: Patients in the control group will perform a combined exercise consisting of aerobic, strengthening and stretching exercises, which will last 45-60 minutes, 3 days a week for 8 weeks, under the supervision of a physiotherapist. At the end of the combined exercise program, they will rest in the relaxation position for 10-15 minutes each session.
Study: NCT04915287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag maleate
Description: 1. Mean baseline platelet count 40 to less than 50 × 10\^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~2. Mean baseline platelet count less than 40 × 10\^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Description: Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: platelet transfusion if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicine
Description: Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
Study: NCT05253417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Cannabidiol (CBD)
Description: For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Cannabidiol (CBD)
Description: For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants take four (4) placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants take four (4) placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg Cannabidiol (CBD)
Description: For the study arm, '100 mg CBD' participants take four (4) CBD capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg Cannabidiol (CBD)
Description: For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
Study: NCT06148649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HEC88473, Placebo, Dulaglutide
Description: T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473, Placebo, Dulaglutide
Description: T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473, Placebo, Dulaglutide
Description: T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473, Placebo, Dulaglutide
Description: T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC88473, Placebo, Dulaglutide
Description: T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
Study: NCT05970354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Cream
Description: Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VersaPro Cream Base for Compounding
Description: Placebo
Study: NCT05836298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
Study: NCT06332508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Description: Device: PEMFs~PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Description: Device: PEMFs~PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy
Description: Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide)~At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy.
Study: NCT05974982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy
Study: NCT05242692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Refer to either S-ketamine or Dexmedetomidine
Study: NCT05058183

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA
Description: Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.
Study: NCT06273254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan Tablets 49mg/51mg
Description: Each tablet contains Sacubitril 49 mg and Valsartan 51 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
Description: Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex
Study: NCT05212740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise program will be performed two times per week for six weeks for 12 sessions.
Study: NCT05140148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills
Study: NCT06465576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin + Mirabegron
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.
Study: NCT05136625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block
Description: A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation
Description: Troncular scalp blockade. Local site infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Preparation
Description: Troncular scalp blockade. Local site infiltration
Study: NCT04956900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurase Wound gel
Description: Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurase Wound gel
Description: Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurase Wound gel
Description: Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurase Wound gel
Description: Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurase Wound gel
Description: Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.
Study: NCT05636631

Intervention type: DEVICE
Intervention: Chest ultrasound
Description: chest ultrasound as a non invasive, low cost \& bedside device for differentiation \& follow up of lung congestion \& pneumonia

Intervention type: DEVICE
Intervention: Chest ultrasound
Description: chest ultrasound as a non invasive, low cost \& bedside device for differentiation \& follow up of lung congestion \& pneumonia
Study: NCT05869006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designed SIA Instrument Supported Interpersonal Relations-Based Group Practice
Description: Group Practice

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group practice
Description: The placebo control group application was carried out simultaneously with the intervention group application, and the group application without active curative content was applied.
Study: NCT06465576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin + Mirabegron
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.
Study: NCT05443724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231 30 mg
Description: Oral tablets
Study: NCT05193279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Study: NCT05035680

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unadjuvanted seasonal influenza vaccine
Description: Single 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)
Description: Single 0.8 mL IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59 adjuvanted seasonal influenza vaccine
Description: Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
Study: NCT05448014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion focused group therapy online
Description: Seven sessions of therapist-led online compassion-focused therapy in groups of 4-8 adolescents with mild to moderate symptoms of distress, anxiety, or depression. Trained therapists administer the CFT program in face-to-face meetings.